
|Videos|December 15, 2017
Novel Agent Active in Refractory Polycythemia Vera
Author(s)John O. Mascarenhas, MD
This video highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.
Advertisement
In this video, John O. Mascarenhas, MD, of the Tisch Cancer Institute at Mount Sinai in New York, highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.
Mascarenhas presented results of the study (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
How Did Daraxonrasib Double Survival in Pretreated Metastatic Pancreatic Cancer?
2
Analyzing the Role of CELMoDs in the Relapsed/Refractory Myeloma Space
3
Tebentafusp Yields Favorable 5-Year OS Data in HLA-A*02:01+ Uveal Melanoma
4
Belantamab Mafodotin Combo for R/R Multiple Myeloma Earns Approval in China
5

























































